NasdaqGS - Nasdaq Real Time Price USD

Schrödinger, Inc. (SDGR)

23.88

0.00

(0.00%)

As of 1:56:41 PM EDT. Market Open.

Schrödinger First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Schrödinger ( NASDAQ:SDGR ) First Quarter 2025 Results Key Financial Results Revenue: US$59.6m (up 63% from 1Q 2024...

Simply Wall St. 7 hours ago

SDGR
0.00%
Q1 2025 Schrodinger Inc Earnings Call

Q1 2025 Schrodinger Inc Earnings Call

Thomson Reuters StreetEvents yesterday

NVS

SDGR
0.00%
Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

Schrodinger Inc (SDGR) reports a 63% revenue increase, driven by software and drug discovery growth, while maintaining a robust cash position.

GuruFocus.com yesterday

SDGR
0.00%

NVS
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates

Schrodinger (SDGR) delivered earnings and revenue surprises of -15.49% and 6.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks yesterday

SDGR
0.00%
Schrödinger Reports Strong First Quarter 2025 Financial Results

NEW YORK, May 07, 2025--Schrödinger, Inc. today announced financial results for the quarter ended March 31, 2025.

Business Wire yesterday

SDGR
0.00%
Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Schrödinger, Inc. ( NASDAQ:SDGR ), is not the largest company out there, but it received a lot of attention from a...

Simply Wall St. 2 days ago

SDGR
0.00%
Schrödinger to Present at BofA Securities 2025 Healthcare Conference

NEW YORK, May 05, 2025--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET.

Business Wire 4 days ago

SDGR
0.00%
Schrödinger Presents New Preclinical Data at AACR Annual Meeting

CHICAGO, April 28, 2025--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related si

Business Wire 11 days ago

SDGR
0.00%
Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential

We recently published a list of Bill Gates’ 10 Stock Positions with Huge Upside Potential. In this article, we are going to take a look at where Schrödinger, Inc. (NASDAQ:SDGR) stands against other top stocks in Bill Gates’ portfolio with huge upside potential. Bill Gates became the youngest billionaire back in 1987 when he took […]

Insider Monkey 16 days ago

SDGR
0.00%
Schrödinger to Announce First Quarter 2025 Financial Results on May 7

NEW YORK, April 23, 2025--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close.

Business Wire 16 days ago

SDGR
0.00%
2 ‘Strong Buy’ Stocks That Are Crashing the Market in April

Stocks are swinging wildly this month, as President Trump’s latest tariff moves continue to send shockwaves through the markets. His across-the-board policy shifts have rattled investors and put heavy pressure on equities, with the S&P 500 down by 8.5% and the NASDAQ by 9% in April. But even when the broader market stumbles, momentum can still drive individual names higher. Ask any pro athlete – momentum is everything. A pitcher hits a rhythm and racks up strikeouts. A point guard gets hot and s

TipRanks 16 days ago

SLP

SDGR
0.00%
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, April 18, 2025--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company’s common stock to six newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of th

Business Wire 21 days ago

SDGR
0.00%
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Schrödinger fair value estimate is US$34.72 Current share...

Simply Wall St. 22 days ago

SDGR
0.00%
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

NEW YORK, April 14, 2025--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration’s (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA’s roadmap encourages a number of computational approaches to predict drug properties. Schrödinger’s widely used computational platform enables highly accurat

Business Wire 25 days ago

SDGR
0.00%
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?

Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 25 days ago

SDGR
0.00%
Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. last month

SDGR
0.00%
Schrödinger to Present Preclinical Data at AACR Annual Meeting

NEW YORK, March 25, 2025--Schrödinger today announced that new preclinical data on SGR-3515 and SGR-4174 will be presented at the AACR Annual Meeting 2025.

Business Wire last month

SDGR
0.00%
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

NEW YORK, March 10, 2025--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025.

Business Wire last month

SDGR
0.00%
Schrödinger Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Schrödinger ( NASDAQ:SDGR ) Full Year 2024 Results Key Financial Results Revenue: US$207.5m (down 4.2% from FY 2023...

Simply Wall St. 2 months ago

SDGR
0.00%
Q4 2024 Schrodinger Inc Earnings Call

Q4 2024 Schrodinger Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

NVS

SDGR
0.00%

Performance Overview

Return	SDGR	S&P 500 (^GSPC)
YTD	+23.79%	-3.68%
1-Year	+3.20%	+8.66%
3-Year	+2.23%	+41.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Schrödinger, Inc. (SDGR)

Schrödinger First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Q1 2025 Schrodinger Inc Earnings Call

Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates

Schrödinger Reports Strong First Quarter 2025 Financial Results

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

2 ‘Strong Buy’ Stocks That Are Crashing the Market in April

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued

Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?

Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans

Schrödinger to Present Preclinical Data at AACR Annual Meeting

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Schrödinger Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Q4 2024 Schrodinger Inc Earnings Call

Performance Overview